News

November 10, 2020

Announcing licensing and partnership for canSEEK™ pan-cancer targeting technology

POINT today announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University...

October 13, 2020

POINT Biopharma Presents at 2020 BIO Investor Forum

POINT Biopharma Inc. announces its CEO Dr. Joe McCann will present at the 2020 BIOInvestor Forum.

August 25, 2020

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits...

August 4, 2020

Announcing our $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits ...

June 23, 2020

ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of ...